Patient Support Programs (PSP) in Egypt: A Practical Guide
Quick answer
How Patient Support Programs improve adherence for chronic disease patients in Egypt, what services they include, and how pharma companies partner with Hospitalia.
Patient Support Programs (PSP) bridge the gap between prescription and outcome. In Egypt, where chronic conditions like diabetes, hepatitis, and oncology require sustained adherence, PSPs deliver nurses, counselors, and home services that keep patients on therapy.
Building or reviewing a PSP for a pharma brand? The market access guide covers the economics, KPIs and launch timeline in depth.
Read the PSP build vs. outsource guideFrequently asked questions
What is a Patient Support Program?
A PSP is a structured program — usually funded by a pharmaceutical company — that supports patients on a specific therapy with education, home injection administration, adherence reminders, side-effect management, and 24/7 nurse hotlines.
Why are PSPs critical in Egypt?
Egyptian studies show 40–60% non-adherence rates for chronic disease therapies. PSPs are proven to lift adherence above 85%, reducing hospitalizations and improving outcomes — especially in diabetes, multiple sclerosis, hepatitis, oncology, and IVF.
What services does a Hospitalia PSP include?
Patient onboarding and education, home injection delivery, vital signs monitoring, side-effect triage, refill reminders, telehealth check-ins, real-world data collection, and pharmacovigilance reporting — all delivered by trained nurses.
Is patient data secure under a PSP?
Yes. Hospitalia's PSP infrastructure is built on encrypted platforms, with consent-based data sharing aligned with Egypt's Personal Data Protection Law and pharma sponsor's pharmacovigilance requirements.
How do pharma companies launch a PSP with Hospitalia?
Hospitalia partners with pharma brand teams to design custom programs covering nurse workforce, IT platform, reporting dashboards, and regulatory compliance. Pilots typically launch within 60–90 days.
